The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
Rainer Kunstfeld
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Axel Hauschild
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono
David Zloty
Consultant or Advisory Role - Genentech
Honoraria - Presentation
Research Funding - MIKIE Vancouver Canada site
Gary Rogers
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Brigitte Dreno
Consultant or Advisory Role - Roche
Honoraria - Roche
Lada Mitchell
Employment or Leadership Position - Roche
Michal Starnawski
Employment or Leadership Position - Roche
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche